Cereno Scientific (CRNO) GoCo Investor Days summary

Strategic focus and business development

• Focus on developing epigenetic modulators for rare cardiovascular and lung diseases, aiming to slow, halt, or reverse disease progression and improve patient outcomes.

• Three programs in the pipeline: two clinical (CS1 for pulmonary arterial hypertension, CS014 for fibrotic lung diseases) and one preclinical.

• Global operations with a small core team and extensive collaborations, including a U.S. subsidiary and partnerships with major institutions.

• Growth achieved through retail investor support, uplisting to NASDAQ, and ongoing business development discussions with pharma companies.

• Actively pursuing potential licensing or acquisition deals with large pharmaceutical companies.

Clinical pipeline and future plans

• CS1 (repurposed VPA) completed Phase 2a in pulmonary arterial hypertension, showing safety, improved heart function, quality of life, and prognosis.

• Extended access program underway with a 12-month readout expected in Q1; Phase 2b global trial to start in the first half of next year.

• CS014 (new chemical entity) completed Phase 1 for fibrotic lung diseases, showing safety and promising exposure; Phase 2 trial planned for next year.

• Both programs aim to offer oral, well-tolerated drugs that can be added to current therapies, targeting improved quality and length of life.

• Study sizes for CS1 expected to be 100-150 patients across 40-50 global sites, with U.S. as a major market.

Regulatory and financial highlights

• CS1 received FDA Fast Track designation, providing regulatory support, increased speed, and cost benefits.

• Investor base grew 20%-25% in the first nine months of the year, with market cap growth and successful financing through debt and share issues.

• Prepared to finance upcoming trials independently or through partnerships, with flexibility for both scenarios.

• Ongoing collaboration with CROs and partners to ensure quality and regulatory compliance in global trials.

• Business model leverages biotech innovation with the goal of eventual pharma partnership for commercialization.